期刊文献+

高迁移率蛋白A2在不同宫颈病变中的表达及意义 被引量:4

Expression and clinical significance of HMGA2 in cervical intraepithelial neoplasms and cervical cancer
原文传递
导出
摘要 目的探讨高迁移率蛋白A2(HMGA2)在不同宫颈病变组织中的表达及其临床意义,了解其与宫颈人乳头瘤病毒(HPV)感染的关系。方法免疫组织化学法检测无锡市第三人民医院2005至2007年30例正常宫颈组织、19例低级别上皮内瘤样病变宫颈组织、16例高级别上皮内瘤样病变宫颈组织、13例宫颈鳞癌组织中HMGA2蛋白的表达,原位杂交检测各组织中HPV感染的情况,分析HMGA2蛋白表达与HPV感染在宫颈病变组织中的相关性。结果正常宫颈组织、CINⅠ级、CINⅡ~Ⅲ级和宫颈浸润性鳞癌组织中,HMGA2蛋白的阳性表达率分别为26.67%、21.05%、68.75%和76.92%。CINI与正常宫颈组织阳性表达率比较,差异无统计学意义;CINⅡ~Ⅲ级、宫颈浸润性鳞癌组织与正常宫颈组织阳性表达率比较,差异有统计学意义(P=0.011,P=0.006)。宫颈高级别上皮内瘤样病变和宫颈癌组织具有较高的HPV感染率,HPV感染与否和HMGA2的表达两者之间未发现统计学相关性。结论HMGA2高表达于高级别宫颈上皮内瘤样病变组织和宫颈癌组织,这可能是宫颈病变的一个早期事件。HMGA2的表达与宫颈HPV感染两者没有相关性,HMGA2可能是宫颈恶性转化的内因之一。 Objective To investigate the expression and clinical significance of HMGA2 in cervical intraepithelial neoplasms and cervical cancer and the relationship with HPV. Methods Expression of HMGA2 protein were retrospectively studied by immunohistochemistry in 30 normal cervical tissues, 19 low grade of cervical intraepithelial neoplasms,16 high grade of cervical intraepithelial neoplasms, 13 cervical squamous cancer. HPV were detected with hybridization in situ. Results The expression of HMGA2 was 26.67%,21.05%,68.75% and 76.92% in normal cervical tissues,CINⅠ,CINⅡ~Ⅲ and cervical squamous cancer respectively (χ2=17.11,P0.001). There was negative correlation between the expression of HMGA2 and HPV infection. Conclusion The abnormality of HMGA2 expression maybe an early event in transformation of cervical cancer. HMGA2 possibility is an intrinsic factor in the transformation for the negative correlation with HPV.
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2010年第3期216-218,共3页 Chinese Journal of Practical Gynecology and Obstetrics
基金 上海市卫生局青年科研基金(2006)
关键词 高迁移率蛋白A2 人乳头瘤病毒 宫颈上皮内瘤样病变 宫颈癌 high mobility group A2(HMGA2) HPV CIN cervical squamous cancer
  • 相关文献

参考文献14

  • 1Cleynen I, Van de Ven WJ. The HMGA proteins: a myriad of functions (Review) [J]. Int J Oncol, 2008, 32(2):289-305.
  • 2Rahman MM, Qian ZR, Wang EL, et al sion of HMGA1 and 2 in gastroenteronan Frequent overexpres- neuroendoerine tumours and its relationship to let-7 downregulation [J]. Br J Cancer,2009,100 (3) :501-510.
  • 3Meyer B, Loeschke S, Schuhze A, et al. HMGA2 overexpression in non-small cell lung cancer[J]. Mol Carcinog, 2007,46: 503-511.
  • 4Malek A, Bakhidze E, Noske A, et al. HMGA2 gene is a promising target for ovarian cancer silencing therapy[J]. Int J Cancer, 2008,123:348-356.
  • 5Jones AM, Mitter R, Poulsom R, et al. mRNA expression profiling of phyllodes tumours of the breast: identification of genes important in the development of borderline and malignant phyllodes tumours[ J]. J Pathol, 2008,216:408-417.
  • 6Bustin M, Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function [J]. Prog Nucleic Acid Res Mol Biol, 1996,54:35-100.
  • 7Yu F, Yao H, Zhu P, et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells [ J ]. Cell, 2007,131 (6) : 1109-1123.
  • 8Park SM, Shell S, Radjabi AR, et al. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2 [ J]. Cell Cycle, 2007,6:2585-2590.
  • 9Di Cello F, Hillion J, Hristov A, et al. HMGA2 participates in transformation in human lung cancer [ J ]. Mol Cancer Res, 2008,6 : 743 -750.
  • 10Lee MY, Chou CY, Tang MJ, et al. Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation [ J ]. Clin Cancer Res, 2008,14:4743-4750.

同被引文献49

  • 1张旗,何湘君,潘秀英.RNA加尾和引物延伸RT-PCR法实时定量检测microRNA[J].北京大学学报(医学版),2007,39(1):87-91. 被引量:23
  • 2宋晓霞,杨秋娟.腹式子宫次切术配伍宫颈环形电切术式探讨[J].中国医药导报,2007,4(10Z):27-27. 被引量:5
  • 3Salani R, Kurman RJ, Giuntoli R, et al. Assessment of TP53 mu- tation using purified tissue samples of ovarian serous cancers re- veals a higher mutation rate than previously reported and does not correlate with drug resistance[ J]. Int J Gynecol Cancer, 2008, 18(3) : 487 -491.
  • 4Mahajan A, Liu Z, Gellert L, et al. HMGA2 : a biomarker signifi- cantly overexpressed in high-grade ovarian serous cancer[ J]. Mod Pathol, 2010, 23(5) : 673 -681.
  • 5Wei JJ, Wu J, Luan C, et al. HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous cancer in fallopian tubes[ J]. Am J Surg Pathol, 2010, 34 (1): 18-26.
  • 6Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution[ J/OL]. J Oncol, 2010:932371 [ 2011-05-07 ]. http ://www. ncbi. nlm.nih.gov/pmc/articles/PMC2739011/? tool = pubmed.
  • 7Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous cancers of tubal origin? [ J]. Am J Surg Pathol, 2010, 34 (10) : 1407 - 1416.
  • 8Diniz PM, Carvalho JP, Baracat EC, et al. Fallopian tube origin of supposed ovarian high-grade serous cancers [ J ]. Clinics ( Sao Paulo), 2011, 66(1): 73-76.
  • 9Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification [ J ]. Int J Gynecol Pathol, 2008, 27 ( 1 ) : 1 - 9.
  • 10Levanon K, Crum C, Drapkin R. New insights into the pathogenc- sis of serous ovarian cancer and its clinical impact[ J]. J Clin On- col, 2008, 26(32): 5284-5293.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部